Home
overview
The pharmaceutical market for osteoporosis is likely to more than double by 2006 as the number of patients affected by the disease continues to steadily increase. There is, therefore, huge potential in the market for osteoporosis therapies, diagnostic techniques and disease management or prevention.

At SMi’s latest conference, ‘Osteoporosis Therapies: Strong Bones for life’, you will join other executives from around the world in exploring the opportunities present in the Osteoporosis market. In two informative days, this conference will discuss the latest drug developments and approaches to the discovery of new drugs, as well as the treatment and prevention of osteoporosis.

Our speakers are experts in their field and will make sure you are well informed on current therapies and diagnostic technologies. They will also cover the practical aspects of osteoporosis such as patient recruitment, regulatory and legal issues and the opportunities within the osteoporosis market, giving you the information you need to help your company prosper.

As usual with SMi pharmaceutical events, there will also be excellent networking opportunities available, allowing you to discuss the main issues with colleagues from all over the world.

So don’t miss out on this excellent opportunity.

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Dr Steven Bain

Dr Steven Bain, Executive Vice President and Chief Scientific Oficer, SkeleTech

9:10 OPPORTUNITIES WITHIN THE OSTEOPOROSIS MARKET

Tim Clay / Jennifer Cassels

Tim Clay / Jennifer Cassels, Healthcare Research Manager / Pharmaceutical Industry Analyst, Frost and Sullivan

  • Epidemiology of osteoporosis
  • The current market situation
  • Issues and challenges within the osteoporosis market
  • Market forecasts
  • Market winners and why
  • Products in the pipeline
  • 9:40 EXOGENOUS OR ENDOGENOUS PTH AS ANABOLIC THERAPIES FOR OSTEOPOROSIS

    Dr Edward Nemeth

    Dr Edward Nemeth, Chief Scientific Officer, NPS Pharmaceuticals

  • Catabolic and anabolic effects of PTH on bone
  • Anabolic effects of exogenous PTH (ALX1-11) in postmenopausal osteoporosis
  • Endogenous level of PTH are controlled by the calcium receptor
  • Calcium receptor antagonists (calcilytics) stimulate new bone formation in animal models of osteoporosis
  • 10:20 CELL THERAPY FOR OSTEOPOROSIS

    Dr Steven Wolff

    Dr Steven Wolff, Vice President Medical Research, Aastrom Biosciences

  • BM derived osteogenic cells
  • Treatment of bone disorders with BMT
  • AastromReplicell Cell Production System
  • Clinical Trial Design
  • Preliminary Trial Results
  • 11:00 Morning Coffee

    11:20 ROLE OF SERMS IN THE LONG-TERM MANAGEMENT OF POSTMENOPAUSAL WOMEN

    Dr Donato Agnusdei

    Dr Donato Agnusdei, Osteoporosis Consultant Europe & Latin America, Eli Lilly

  • Skeletal effects of Raloxifene (EvistaTM)
  • Early and sustained efficacy of Evista to prevent fractures in patients with osteoporosis
  • Extraskeletal effects of Evista
  • Safety profile of Evista
  • Clinical use of Evista in postmenopausal women
  • 12:00 NO-RELEASING DRUGS AS POTENTIAL INHIBITORS OF BONE RESORPTION

    Dr Piero Del Soldato

    Dr Piero Del Soldato, Executive Vice President, Science & Technology, NicOx

  • Role of NO on bone loss
  • Rationale for the use of a NO-NSAID
  • In vitro data
  • In vivo animal data
  • Safety profile in animals
  • Results of first clinical trials
  • 12:40 Networking Lunch

    14:00 BISPHOSPHONATE THERAPIES

    Dr Andreas Grauer

    Dr Andreas Grauer, European Medical Director Bone, Procter & Gamble

  • Changing the osteoporosis paradigm- the need for speed!
  • Rapid reduction of vertebral fractures
  • The relative importance of surrogate endpoints
  • Are all bisphosphonates the same?- safety considerations
  • 14:40 MECHANICAL STIMULATION AS A TREATMENT FOR OSTEOPOROSIS

    Dr Steven Bain

    Dr Steven Bain, Executive Vice President & Chief Scientific Officer, SkeleTech

  • Functional load bearing and the maintenance of bone mass
  • If physiologic strains prevent bone loss, why doesn’t exercise work?
  • Augmentation of bone mass by low level mechanical stimuli
  • Synergistic optimisation of drug therapies by mechanical loading
  • The use of mechanical loading paradigms as a tool for a gene discovery and target validation
  • Is mechanical stimulation of skeleton an alternative to anti-osteoporotic drugs?
  • 15:20 Afternoon Tea

    15:40 RANKL AUTOVAC PHARMACCINE

    Dr Marc Hertz

    Dr Marc Hertz, Project Manager, Pharmexa

  • The AutoVac approach: targeting pathogenic self-proteins
  • Advantages of AutoVac: active versus passive immunotherapy
  • Bypassing immune tolerance and generating anti-RANKL humoral responses
  • RANKL AutoVac in models of osteoporosis and bone loss
  • 16:20 HORMONE REPLACEMENT THERAPY

    Stephen Simes

    Stephen Simes, President and Chief Executive Officer, BioSante Pharmaceuticals

  • Evaluation of HRT: advantages and benefits
  • HRT controversies in therapy-why the hype?
  • Estrogen for women: why is it a multibillion-dollar market?
  • Testosterone for women: the missing link?
  • Testosterone for men: treating the other 20% of osteoporosis
  • ‘New’ treatment modalities
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr Juliet Compston

    Dr Juliet Compston, Reader in Metabolic Bone Disease and Honorary Consultant Physician, University of Cambridge

    9:10 BONE MARKERS

    John Curtis

    John Curtis, Managing Director, Diagnostics, Provalis

  • Current tests for bone markers
  • Comparison of Bone Mineral Density and bone markers
  • Bone markers as therapy monitors
  • Bone markers and the diagnosis of osteoporosis
  • Do bone markers tell us more than BMD?
  • Theranostic opportunities
  • 9:40 IDENTIFICATION AND VALIDATION OF CATHEPSIN K AS A DRUG DISCOVERY TARGET

    Dr Michael Lark

    Dr Michael Lark, Director, Musculoskeletal Diseases Biology, GlaxoSmithKline

  • Validation of cathepsin K as a bone anti-resorptive target
  • Evaluation of compound activity in vitro
  • Challenges of development of compounds with in vivo activity targeted to the enzyme
  • 10:20 USING HUMAN POPULATION GENETICS TO IDENTIFY THE KEY TARGETS FOR OSTEOPOROSIS DRUG DISCOVERY

    Dr Patrick Kleyn

    Dr Patrick Kleyn, Chief Scientific Officer, Gemini Genomics

  • Putting together a world-leading clinical resource made up of thousands of DNA samples derived from patients and healthy volunteers from across the globe
  • Integrating SNP and clinical information to identify the key gene targets and diagnostics that will revolutionise the management of common diseases
  • A large clinical collection: encompassing both healthy and osteoporosis patients assessed in details for clinical markers relevant to bone metabolism
  • Using these resources: identifying several genes that regulate bone density and architecture and predispose to risk of fracture
  • 11:00 Morning Coffee

    11:20 THE FUTURE OF OSTEOPOROSIS DRUG DEVELOPMENT

    Dr simon Bennett

    Dr simon Bennett, Programme Director, Oxagen

  • The need for novel targets
  • Strategies for novel target discovery
  • Integrated exploration: genetics, genomics and proteomics
  • The importance and power of clinical genetics in target validation
  • The role of pharmacogenetics
  • 12:00 ChronOS- A PROMISING BONE SUBSTITUTE AND DRUG CARRIER

    Stoll Thierry

    Stoll Thierry, Manager Development, Mathys Medical

  • Synthetic materials
  • Porous ceramics
  • Calcium phosphate
  • In vivo study
  • Spinal application
  • Reabsorption
  • 12:40 Networking Lunch

    14:00 HOW GENOMIC INFORMATION CAN BE USED IN OSTEOPOROSIS RESEARCH

    Dr Karen Jones

    Dr Karen Jones, European Product Sales Specialist, Incyte Genomics

  • Application of genomics for new target identification in osteoporosis
  • Functional genomic approaches to target validation
  • The future of genomics in osteoporosis drug development
  • 14:40 PREVENTION OF OSTEOPOROSIS

    Dr Leena Norri

    Dr Leena Norri, Medical Adviser, Orion Pharma

  • HRT: different regimens
  • Low dose regimens
  • Changes in BMD
  • Compliance
  • 15:20 Afternoon Tea

    15:40 LEGAL ISSUES FOR CONSIDERATION

    Marjan Noor

    Marjan Noor, Solicitor, Taylor Joynson Garrett

  • General background
  • Medical use patents
  • Methods of treatment
  • Patenting gene sequences
  • Licensing patents
  • 16:20 PATIENT RECRUITMENT INTO OSTEOPOROSIS TRIALS

    Dr Ian Smith

    Dr Ian Smith, Medical Director, Synexus

  • Population screening
  • Other recruitment methods
  • Review of Synexus screening database
  • Mailshots and advertising
  • The recruitment funnel
  • Patient retention
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.